Docking Studies, Synthesis, Characterization and Evaluation of Their Antioxidant and Cytotoxic Activities of Some Novel Isoxazole-Substituted 9-Anilinoacridine Derivatives

Table 2

Short term in vitro anti-tumor activity of synthesized compounds against Daltons Lymphoma Ascites (DLA) cells.

S. No	Compound	Concentration (μg/mL)	% viability	% cytotoxicity	Cyto50 (μg/mL)
(1)	5a	1000	35.83	65.83	679.08
		500	58.02	41.98
		250	75.58	24.42
(2)	5b	1000	40.56	59.44	853.95
		500	65.29	34.71
		250	75.54	24.46
(3)	5c	1000	35.23	64.77	788.77
		500	65.17	34.83
		250	78.66	21.34
(4)	5d	1000	43.33	56.57	518.29
		500	50.57	49.43
		250	70.27	29.73
(5)	5e	1000	45.78	54.22	947.96
		500	77.27	22.73
		250	85.71	14.29
(6)	5f	1000	46.87	53.13	633.71
		500	59.35	40.65
		250	88.26	11.74
(7)	5g	1000	46.38	53.62	938.70
		500	69.98	30.31
		250	79.67	20.33
(8)	5h	1000	32.50	67.50	539.81
		500	53.33	46.67
		250	81.70	18.30
(9)	5i	1000	38.37	61.63	311.75
		500	48.42	51.58
		250	58.33	41.67
(10)	5j	1000	47.11	52.89	930.27
		500	71.51	28.49
		250	89.32	10.68